Sign in
Not yet taking people in South KoreaNo phase

Angionix Balloon for Opening Blocked Heart Arteries in Coronary Artery Disease

Follows people with coronary artery disease treated with the Angionix Balloon.

Key facts

Who runs it
Yonsei University
Where
Daegu, Jeonju, and Yongin, South KoreaSee the 3 sites
Trial code
Registry title
Efficacy and Safety of the Angionix Balloon in Patients With Coronary Artery Disease Undergoing PTCA
Status
Not yet recruiting
People taking part
600 people, planned
Started
9 Nov 2026
Expected to end
1 Jul 2028
Type of study
Observational
Treatments tested
  • Angionix Balloon
Record updated
9 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with coronary artery disease who need a balloon procedure (PTCA) with the Angionix Balloon or Angionix NC Balloon.

Age
19 years or older
Sex
Men and women can join.
Disease stage
Coronary artery disease that needs percutaneous transluminal coronary angioplasty (PTCA).

Main reasons for not taking part

  • Cardiogenic shock, as judged by the investigator
  • Vessel dissection already seen on coronary angiography before the PTCA procedure
  • Pregnant or breastfeeding women
  • Other significant findings that the investigator judges make taking part unsuitable

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Adult aged 19 years or older at baseline
  • Patients diagnosed with coronary artery disease
  • Patients requiring percutaneous transluminal coronary angioplasty (PTCA) with Angionix Balloon or Angionix NC Balloon
  • Patients who voluntarily agree to participate in this study and sign an informed consent form

Who cannot take part

  • Patients with vessel dissection already identified on coronary angiography prior to PTCA procedure based on the investigator's clinical judgment
  • Patients presenting with cardiogenic shock based on the investigator's clinical judgment
  • Pregnant or lactating women
  • Patients who have other clinically significant findings that make them unsuitable for study participation based on the investigator's medical judgment

Where in South Korea

  • Kyungpook National University College HospitalDaegu, South KoreaContact: Yongcheol Kim, MD.,PhDNot yet recruiting
  • jeonbuk National University HospitalJeonju, South KoreaContact: Yongcheol Kim, MD.,PhDNot yet recruiting
  • Yongcheol KimYongin, South KoreaContact: Yongcheol Kim, MD.,PhDNot yet recruiting

About the trial

What the trial wants to find out

A Multi-center, Registry evaluating the efficacy and safety of the use of Angionix Balloon in Patient with Coronary Artery Disease

The group in the trial

  • Angionix Registry Cohort

    Adult patients aged 19 years or older with coronary artery disease who require percutaneous transluminal coronary angioplasty (PTCA) using Angionix Balloon or Angionix NC Balloon.

    Treatment: Angionix Balloon

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multi-center, Registry Evaluating the Efficacy and Safety of the Use of Angionix Balloon in Patient With Coronary Artery Disease
Plain-language title
Angionix Balloon for Opening Blocked Heart Arteries in Coronary Artery DiseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 13 November 2026.
Record updated
9 October 2026